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Abstract: Drug metabolism in human liver is a process involving many different enzymes. 
Among them, a number of cytochromes P450 isoforms catalyze the oxidation of most of 
the drugs commercially available. Each P450 isoform acts on more than one drug, and one 
drug may be oxidized by more than one enzyme. As a result, multiple products may be 
obtained from the same drug, and as the metabolites can be biologically active and may 
cause adverse drug reactions (ADRs), the metabolic profile of a new drug has to be known 
before this can be commercialized. Therefore, the metabolites of a certain drug must be 
identified, synthesized and tested for toxicity. Their synthesis must be in sufficient 
quantities to be used for metabolic tests. This review focuses on the progresses done in the 
field of the optimization of a bacterial self-sufficient and efficient cytochrome P450, P450 
BM3 from Bacillus megaterium, used for the production of metabolites of human enzymes. 
The progress made in the improvement of its catalytic performance towards drugs, the 
substitution of the costly NADPH cofactor and its immobilization and scale-up of the 
process for industrial application are reported. 
Keywords: cytochromes P450; drug metabolite; active metabolite; toxicity test; adverse 
drug reactions  
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1. Introduction 
Drug discovery is a long and expensive process requiring many different steps starting from 
formulation up to preclinical and clinical trials [‎1]. Two of the main causes of human drug failures are 
lack of effectiveness and safety [‎2]. For this reason, it is important to understand at early stages how 
fast a drug is metabolized to assess its effectiveness, as well as to identify and test all the metabolites 
for their possible biological activity.  
In certain cases, a metabolite can have the same effect of the parent drug. For example, one of the 
metabolite of propranolol, a non-selective β-blocker used to treat hypertension, anxiety and panic, is 
4'-hydroxypropranolol. This compound has been demonstrated to have similar effects of propranolol as 
a β-receptor antagonist [‎3] and it is believed to contribute to the bioactivity of this drug [‎4]. Other 
monohydroxylated products of this drug have also been reported to be active as β-blockers [‎5].  
Since the early 70s, it has been known that active metabolites can cause the so-called adverse drug 
reactions (ADRs) [‎6–8]. For example, it has been widely demonstrated that bioactivation of drugs can 
cause DNA modification and relevant mutations for cancer developmet [‎6]. The toxic effects of drugs 
became known in 1973, concerning the anti-inflammatory agent and hepatotoxic acetaminophen [‎9]. It 
was then demonstrated that a reactive quinone–imine intermediate derived from a cytochrome P450 
mediated oxidation of this drug was able to deplete the endogenous antioxidant glutathione (GSH) 
and/or to bind covalently liver proteins leading to hepatic toxicity [‎10].  
It also has to be taken into account that some drugs are administrated as pro-drugs and they are not 
biologically active if not converted into an active metabolite. This is the case of terfenadine that is 
converted into fexofenadine, a molecule active as non-sedating histamine H1 receptor antagonist [‎11]. 
All these considerations point out that safety issues are crucial for drug approval by the FDA, and 
that not only the drug candidate has to be tested for toxicity, but also the effects of its metabolites must 
be known to avoid ADRs. Such studies can require large quantities of the pure metabolites, and these 
may be difficult to synthesize by conventional chemical methods.  
2. Phase I Drug Metabolism 
Cytochromes P450 (CYPs) are a large superfamily of heme-containing monoxygenases mainly 
catalyzing C–H hydroxylations on endogenous and exogenous compounds [‎12]. Though hydroxylation 
is the predominant catalyzed reaction, many other different oxidations can be performed by these 
enzymes on a wide range of structurally different substrates [‎13–15]. This makes it difficult to predict 
a priori the reaction product generated from a given substrate. 
Human cytochromes P450 are enzymes anchored to the endoplasmic reticulum (ER) via a  
N-terminal sequence [‎16,‎17] and they require a redox partner, cytochrome P450-reductase (CPR) to 
perform their function [‎18]. CPR is also anchored to the ER membrane, and its role is to transfer the 
electrons from NADPH to the heme cofactor of the P450. In human liver, cytochromes P450 play a 
predominant role in phase-I drug metabolism and clearance since they turn over the large majority of 
the known commercially available drugs into one or more metabolites [‎13].  
The isoforms CYP3A, CYP2D6, CYP2C, CYP1A2 and CYP2E1 are responsible for the 
metabolism of 80% of the clinically used drugs [‎19,‎20]. However, different metabolites can be 
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produced by one or more isoforms of cytochromes P450 and the metabolites produced by one enzyme 
can be the substrates for a different isoform of P450. As a consequence the metabolite profile of a drug can 
be quite complex taking also into account that different oxidative reactions can take place on different 
attack positions, depending also on the orientation of the drug in the active site of the P450 enzyme.  
Two key steps are required during drug discovery: the first is the identification of all the 
metabolites produced for a given drug [‎21], and the second is the synthesis of these compounds for 
toxicity tests.  
The need to deal with complex metabolite profiling in conjunction with a number of human 
cytochromes P450 has led to the creation of a microfluidic integrated electrochemical system that 
presents the added advantage of the use of 30 μL of drug solution, with the attractive possibility of 
further miniaturization. The use of an autosampler as the pumping system performs the double role of 
increasing the repeatability and controlling the flow with the added potential of ease of integration in 
the robotic high throughput system currently available in the pharmaceutical industry. The system 
allows us not only to electrochemically determine kinetic parameters such as the KM of a drug for a 
given P450, but it also makes possible the product identification by HPLC-MS [‎22]. 
Chemical methods are often difficult to develop for certain metabolites and are not cost-effective. 
An alternative to chemical synthesis is to use cytochromes P450 to generate the metabolites of drugs. 
For this reason, human liver microsomes or human P450 enzymes heterologously expressed in  
bacteria [‎23,‎24] and in insect cells [‎25], and purified have been employed as potential candidates for 
biocatalysis to prepare sufficient quantities of human drug metabolites for toxicity tests. In general, the 
engineering of mammalian P450s as versatile biocatalysts for many biotechnological applications has 
been reported [‎26–31]. However, hepatic microsomes have limited availability and highly variable 
expression levels of cytochromes P450 whereas the human purified enzymes show low catalytic 
activity and poor stability for industrial use [‎32,‎33]. One of the solutions to this issue is the use of other 
P450 enzymes as surrogate for the synthesis of human metabolites. This will be the focus of this review. 
3. P450 BM3 as Biocatalyst 
Cytochrome P450 BM3 from Bacillus megaterium can offer a solid alternative for the synthesis of 
drug metabolites at industrial scale. In fact, the enzyme (CYP102A1) is a soluble and self-sufficient 
enzyme with a diflavin-containing reductase fused to a heme-containing P450 domain in a  
single polypeptide chain. It has been discovered in Bacillus megaterium [‎34] and it acts as a fatty  
acids oxygenase displaying a high activity (>1000 turnovers/min) and nearly 100% coupling  
efficiency [‎35,‎36]. It can be expressed at high levels in recombinant E. coli and it is able to turn over 
different substrates. In 2007, our group demonstrated the ability of wild-type P450 BM3 to turn over 
different drugs [‎37]. We used a screening assay procedure developed in our lab, the so-called alkali 
assay [‎38], to test the ability of the purified enzyme to turn over different drugs usually metabolized by 
different subfamilies of human P450s. Some of the drugs resulted positive to the assay and were 
selected for further studies aimed to identify the metabolites. The enzyme is able to perform different 
reactions on different drugs, including N-dealkylation of propranolol, hydroxylation of chlorzoxazone 
and dehydrogenation of nifedipine [‎37]. Phylogenetic analysis shows that P450 BM3 (CYP102) is very 
Int. J. Mol. Sci. 2012, 13 15904 
 
close to the human counterparts, specifically P450 3A4, when considering the main human enzymes 
involved in drug metabolism (Figure 1).  
Figure 1. Phylogenetic tree based on the sequences of P450 BM3 (CYP102A1) and the 
major human isoforms involved in drug metabolism. The unrooted phyolgenetic tree was 
built aligning the substrate recognition sites (SRS) of the chosen P450s.  
 
Very recently, we also tested a small library of 1,2,5-oxadiazole derivatives, a class of drug 
candidates acting as NO pro-drugs donors for the treatment of cardiovascular diseases on the wild-type 
protein and nine of them resulted to be turned over by the bacterial enzyme, with coupling efficiency 
ranging from 55% to 100% [‎39]. 
The high efficiency and versatility of P450 BM3 are the main reasons why it is considered a 
prototype for a biocatalyst with human P450 activities [‎40–42] offering a solid scaffold for 
biotechnological applications [‎43] including drug metabolite production [‎44].  
4. Optimization of P450 BM3 as a Biocatalyst for Drug Metabolites Production  
The exploitation of the bacterial enzyme as biocatalyst for the production of drug metabolites 
requires a multi-step approach aimed at the optimization of the enzyme performance by protein 
engineering and the development of a platform allowing the regeneration/avoidance of the NADPH 
cofactor and the immobilization for re-usage of the biocatalyst to reduce costs (Figure 2). 
Thus far the scientific literature has been focused on the following goals: 
(1) The increase of the substrate specificity by protein engineering; 
(2) The improvement of the catalytic performance (KM, kcat, coupling efficiency) of P450 BM3 
toward drugs; 
(3) The substitution of the costly NADPH cofactor; 
(4) The immobilization and scale-up of the process for industrial application. 
The achievements in these fields of endeavor are reported here. 
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Figure 2. Steps for the application of P450 BM3 as biocatalyst for the synthesis of  
drug metabolites. 
 
4.1. Protein Engineering to Improve Substrate Selectivity 
The availability of the crystal structure of the heme domain of P450 BM3 in the substrate-free  
form [‎45] and in complex with the palmitoleic acid [‎46] offers the opportunity to identify key residues 
for substrate binding and catalysis and therefore to carry out mutagenesis experiments. Molecular 
docking simulations are also a very useful tool to predict if a drug would enter the catalytic pocket of 
the bacterial enzyme and to understand how the substrate should be oriented in the active site  
for hydroxylation.  
Mutagenesis has been extensively used on P450 BM3 to introduce new abilities to metabolize drugs 
or to improve the existing ones. The strategies used are site-directed mutagenesis, site-saturation 
mutagenesis, directed evolution or a combination of the three approaches. Different metabolites of 
different drugs have been produced and identified using a panel of variants, some of them sharing 
some critical mutations. The variants generated up to now cover a wide range of structurally different 
drugs and often give rise to different metabolites, summarized in Table 1, with different yield. The 
availability of several crystal structures of P450 BM3 mutants [‎47] gives also the opportunity to 
perform docking simulations and to have important information not only on how to further improve the 
biocatalyst but also, more generally, on the structure-function relationship of the enzyme. 
A first experimental evidence that cytochrome P450 BM3 can bind drug-like molecules came in 
2005 from the work of Van-Lussenburg and co-workers [‎48]. A panel of variants of the bacterial 
enzyme was generated and showed the ability to turn over the fluorescent substrates alkoxyresorufins. 
The alkoxyresorufins O-dealkylation assay allowed to test 45 drug-like molecules and demonstrated 
for the first time that variants of the bacterial enzyme can be inhibited by drug-like molecules and 
therefore can bind them [‎48].  
Int. J. Mol. Sci. 2012, 13 15906 
 
Table 1. Drugs and corresponding metabolites produced by WT and mutants of 
cytochrome P450 BM3. 
Drug Structure 
Metabolite produced by  
P450 BM3 WT or variants 
Main human 
P450 involved 
Ref. 
Acetaminophen 
 
N-acetyl-p-benzo-quinone imine [‎49] 2E1 [‎50] 
Amitriptyline 
 
Nortriptyline [‎51] 2C19, 3A4, 1A2 [‎52] 
Amodiaquine 
 
N-desethylamodiaquine [‎53] 2C8 [‎54] 
Astemizole 
 
6-hydroxyastemizole [‎55] 
6-hydroxydesmethylastemizole [‎55] 
Desmethylastemizole [‎55] 
Norastemizle [‎55] 
2D6  
2D6  
2D6  
3A4  
[‎56] 
Buspirone 
 
(R)-6-hydroxybuspirone [‎57] 
Mono- and dihydroxylated metabolites [‎51] 
3A4 
3A4 
[‎58] 
Chlorzoxazone 
 
6-hydroxychlorzoxazone [‎37] 2E1 [‎59] 
Cilostazol 
 
Mono- and di-hydroxymetabolites [‎51] 3A4/5 [‎60] 
Citalopram 
 
Demethylcitalopram [‎51]  
di-demethylcitalopram [‎51] 
3A4, 2C19 
2D6 
[‎61] 
Clozapine 
 
N-demthylclozapine [‎62]  
Clozapine N-oxide [‎62] 
1A2  
1A2 
[‎63] 
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Table 1. Cont. 
Drug Structure 
Metabolite produced by  
P450 BM3 WT or variants 
Main human 
P450 involved 
Ref. 
Dextromethorpha
n 
 
3-methoxymorphinan [‎49] 2D6, 3A4 [‎64] 
Diclofenac 
 
4'-hydroxydiclofenac [‎65,‎66]  
5-hydroxydiclofenac [‎65] 
2C9/2C19  
2C9/2C19 
[‎67] 
Diltiazem 
 
Demethyldiltiazem [‎51] 
Di-demethyldiltiazem [‎51] 
3A4  
3A4 
[‎68] 
Irbesartan 
 
Hydroxyirbesartan [‎51]  
Di-hydroxyirbesartan [‎51] 
2C9  
2C9 
[‎69] 
Lovastatin 
O
O
OH
O
O
H
 
6b-hydroxylovastatin [‎70]  
6'-exomethylenelovastatin [‎70] 
3A4/5  
3A4/5 
[‎71] 
Naproxen 
 
Desmethylnaproxen [‎47] 2C9, 1A2 [‎72] 
Nifedipine 
 
Oxidized nifedipine [‎37] 3A4 [‎73] 
Ondansetron 
 
Hydroxylondansetron [‎51]  
Dihydroxyondansetron [‎51] 
3A4, 2D6, 1A2  
3A4, 2D6, 1A2 
[‎74] 
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Table 1. Cont. 
Drug Structure 
Metabolite produced by  
P450 BM3 WT or variants 
Main human 
P450 involved 
Ref. 
Phenacetin 
 
Acetaminophen [‎75] 1A2 [‎76] 
Propafenone 
 
Hydroxylated metabolites [‎51]  
N-despropylpropafenone [‎51] 
2D6  
3A4/1A2 
[‎77] 
Propranolol 
 
4'-hydroxypropranolol [‎78]  
5'-hydroxypropranolol [‎78] 
N-despropylpropranolol [‎37,‎78] 
2D6 
2D6 
1A2 
 
[‎79] 
Repaglinide 
 
Hydroxylated metabolites [‎80] 3A4, 2C8 [‎81] 
Simvastatin H
O
OH O
O
O
 
6b-hydroxysimvastatin [‎70] 
6'-exomethylenesimvastatin [‎70] 
3A4 
3A4 
[‎71] 
Tolbutamide 
 
4-hydroxytolbutamide [‎37] 2C [‎82] 
Verapamil 
 
Norverapamil [‎55] 
D-617 [‎55] 
D-620 [‎55] 
D-702 [‎55] 
PR-22 [‎55] 
PR-25 [‎55] 
3A4 
3A4/3A5, 2C8 
3A4/3A5, 2C8 
2C9/2C18 
2C8 
2C8 
[‎83] 
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In 2006, site saturation mutagenesis toward selected active site residues (A74, L75, V78, P81, A82, 
F87, and T88) was applied in combination with random mutagenesis and allowed the generation of a 
mutant able to produce three metabolites of the drug propranolol (4-hydroxy-, 5-hydroxy- and  
N-despropylpropranolol) [‎78]. If we consider that the wild type enzyme is able to produce only one 
metabolite corresponding to the N-desproylated form of propranolol [‎37], this is a very good 
demonstration of how the bacterial P450 BM3 is an optimal template for protein engineering and a 
versatile enzyme able to perform different reactions and attack different positions.  
Site-directed mutagenesis was also used to create a panel of mutants of P450 BM3, able to 
metabolize probe substrates for human cytochromes P450 such as 7-ethoxycoumarin that is widely 
used to measure the drug metabolizing activity in liver and testosterone, that is widely used to probe 
the activity of P450 3A4. The P450 BM3 variants were shown to perform 3-hydroxylation and  
O-deethylation, producing the typical metabolites of human enzymes [‎41]. The rates for the two 
reactions were increased by up to 61- and 129-fold with respect to wild type for the O-deethylation and 
3-hydroxylation reactions, respectively. 
In 2006, the triple mutant R47L/F87V/L188Q was found to metabolize testosterone  
as well as other molecules such as amodiaquine, dextromethorphan, acetaminophen, and  
3,4-methylenedioxymethylamphetamine (MDMA) [‎49]. Testosterone was converted into three 
metabolites that were found to be monohydroxylated derivatives of the drug. One of them resulted to 
be 16β-hydroxytestosterone whereas 6β-hydroxytestosterone, the major metabolite formed by human 
P450 3A4 [‎73], was not detected. However, very recently, a single mutation (A82W) introduced in two 
previously generated P450 BM3 variants was reported to improve the regioselectivity toward steroid 
hydroxylation in position 16β [‎84]. Furthermore, the single active site mutation S72I introduced in the 
same variants resulted to invert the stereoselectivity producing 16α-hydroxytestosterone [‎85]. These 
data are again an excellent example of how the bacterial enzyme can be manipulated toward the 
desired and enantiospecific function. 
The triple mutant R47L/F87V/L188Q showed also new catalytic abilities with respect to the  
wild-type enzyme concerning the conversion of amodiaquine into two metabolites identified by MS 
analysis as N-desethylamodiaquine and a monohydroxylated metabolite [‎49]. Also dextromethorphan 
resulted to be N-demethylated to form the metabolite 3-methoxymorphinan and MDMA was 
metabolized by the bacterial triple mutant to three metabolites: 3,4-methylenedioxyamphetamine 
(MDA), N-hydroxy-3,4-methylenedioxym-ethylamphetamine (N-OH-MDMA) and 3,4-dihydroxy-
methylamphetamine (3,4-OH-MA). Acetaminophen was also metabolized by P450 BM3 
R47L/F87V/L188Q to the N-acetyl-p-benzoquinoneimine (glutathione conjugate) [‎49]. The rates of 
product formation resulted lower than those measured for the human enzymes for the same 
metabolites, but the triple mutant was then used as a template for a round of random mutagenesis to 
create a new library of variants. Two more rounds of random mutagensis allowed the generation of 
four mutants (M01, M02, M05 and M11) with improved activity toward dextromethorphan and 
MDMA in comparison to the starting variant [‎53]. The product formation was increased up to 200-fold 
for dextromethorphan when compared to the triple mutant and the activities of the random mutants 
resulted up to 90-fold higher than the values reported for human P450 2D6 [‎53]. In this work, three 
key mutations were identified (F81I, E267V, L86I) and, interestingly, one of them (L86I) was not 
located in the active site.  
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The four mutants M01, M02, M05 and M11 were also found to generate the same GSH adducts 
of diclofenac, as the one obtained with incubations with human liver microsomes [‎62,‎65]. In 
particular, P450 BM3 M11 yielded similar oxidative metabolite profiles of diclofenac as human P450s, 
producing also 4'-hydroxy- and 5-hydroxydiclofenac. This mutant was therefore expressed in yeast 
that was used as model system for toxicity studies on the metabolites of diclofenac, a drug known to 
induce severe liver toxicity [‎86]. The results showed that yeast strains expressing P450 BM3 M11 
grew significantly slower in the presence of diclofenac than the control strains not expressing the P450 
enzyme. The metabolites 4'- and 5-hydroxydiclofenac did not show any effect on cell growth in cells 
expressing P450 BM3 M11, suggesting that they are not involved in yeast toxicity [‎49]. This work 
represents a pioneer study in a model system; however it demonstrates the feasibility to use bacterial 
P450 BM3 variants also directly in cells to perform toxicity tests. 
In a recent work of our group, a mutant carrying two mutations generated by random mutagenesis, 
showed the new abilities to metabolize diclofenac, ibuprofen and tolbutamide to 4'-hydroxydiclofenac, 
2-hydroxyibuprofen and 4-hydroxytolbutamide, respectively [‎66]. The mutant, named A2, also in this 
case carries the two mutations far away from the active site (Figure 3) and it is very interesting since  
it can generate the human metabolites of three drugs usually metabolized by CYP2C subfamily in 
human liver.  
Figure 3. Structure of the heme domain of P450 BM3 in complex with the substrate 
palmitoleic acid (magenta) [‎46]. The yellow circles indicates the residue mutated in the variant 
A2, that can metabolize diclofenac, ibuprofen and tolbutamide. The heme is shown in red. 
 
Other variants able to convert ibuprofen were generated by directed evolution [‎47]. These variants 
showed also a new activity toward desmethylnaproxen that is the human metabolite of naproxen, 
another substrate of CYP2C9 in vivo [‎47]. It is remarkable that all these data suggest indeed that it is 
possible to produce different bacterial mimics of each human P450 both in terms of substrate 
specificity and metabolic profile. Furthermore, the crystal structure of an early intermediate in directed 
evolution experiments was solved and showed the effect of a critical residue of the active site (L75R) 
in increasing the flexibility of B'-helix [‎47]. It is therefore important to use also random approaches to 
engineer the bacterial enzyme to introduce mutations that change the flexibility of the protein that can 
be crucial to accommodate new substrates. Often changes in flexibility are due to mutations far away 
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from the active site and therefore unpredictable by rational design approaches. The other advantage of 
directed evolution approaches is the generation of libraries of mutants, increasing the chance to obtain 
variants that perform multiple reactions including the desired one. This was the case of the generation 
of 43 mutants active toward verapamil [‎55], a calcium channel blocker used in the treatment of 
hypertension and arrhythmia [‎87]. The variants derived from mutants previously generated for the 
conversion of propranolol [‎78] and for stereoselective and enantioselective alkane hydroxylation [‎88,‎89]. 
Some of the variants were chimeric forms derived from the recombination of CYP102A1 with other 
bacterial enzymes belonging to the CYP102A subfamily (see paragraph 4.2). Ten different metabolites 
were produced and six of them are the ones typically produced by human P450 3A4 [‎90]. In the work 
of Sawayama and co-workers [‎55], 42 variants active toward astemizole, a potent H1-histamine 
receptor antagonist used for treatment of common sinus allergy symptoms, were also generated 
producing seven different metabolites, four of them produced by human enzymes [‎80]. 
In the same work, variants able to metabolize a third compound, LY294002, an antiproliferative 
agent that inhibits phosphatidylinositol 3-kinase [‎91] were also generated and produced 2 hydroxylated 
products also produced by human enzymes. Interestingly, the LY294002 conversion by the variants 
resulted lower (<15%) than the ones obtained for verapamil (85%) and astemizole (85%). However 
this trend correlates with the profile obtained with rat liver microsomes, demonstrating that the 
compound LY294002 is less prone to C–H oxidation catalyzed by P450 enzymes than verapamil and 
astemizole [‎91]. These data point out one of the other advantages in the use of bacterial P450s as 
surrogate of the human enzymes, sharing general reactivity features. 
It has to be taken into account that enantioselectivity is often a very important requirement for the 
synthesis of some drug metabolites and it often represents a limit of chemical synthetic methods. 
However, this kind of selectivity has been achieved by the work mentioned above [‎55] where a single 
mutation resulted to invert the enantioselectivity for 16-testosterone. Furthermore, a mutant of P450 
BM3 able to metabolize buspirone into the metabolite (R)-6-hydroxybuspirone that was the sole 
product [‎57] was also produced and a high yield of conversion achieved (72% in 7 h).  
Human chiral metabolites of simvastatin and lovastatin were also obtained by wild type P450 BM3 
and the activity toward these two drugs was increased in two variant carrying six and seven mutations, 
generated by site-directed mutagenesis [‎70]. These two drugs are used to treat hyperlipidemia and 
hypercholesterolemia and are usually oxidized by human CYP3A4/5 to several products, including 
6'b-hydroxy, 3-hydroxy- and exomethylene metabolites. The mutants not only resulted to produce the 
correct chiral compound but also showed a catalytic efficiency higher than the one reported for human 
P450 3A4 with a kcat/Km up to 7-fold higher than the human enzyme [‎70]. 
P450 BM3 variants were found to metabolize clozapine, an antipsychotic drug and acetaminophen, 
a widely used analgesic and antipyretic drug, at significantly higher (up to 70-fold) levels than human 
and rat microsomes [‎62]. This drug is mainly metabolized by human P450 1A2 [‎92]. The oxidation of 
other substrates metabolized by P450 1A2 was achieved also by site directed mutagenesis. Mutants 
with improved activities toward phenacetin, ethoxyresorufin and methoxyresorufin respect to the wild 
type enzyme were generated and the O-deethylation product of phenacetin obtained [‎75]. 
The increasing need to identify new advantageous mutations for the production of metabolites from 
drugs covering a large fraction of the chemical space led to the design of an experimental strategy 
aimed at the generation of a minimal set of BM3 mutants with differences in regio- and 
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stereoselectivities toward a library of drugs [‎51]. In this work, drug depletion by five different mutants 
was observed for 43 molecules. Furthermore, LC-MS analysis performed in selected single ion modes 
allowed the identification of multiple metabolites for nine drugs. Some of them are produced also by 
human liver microsomes (HLM) whereas others resulted specific for P450 BM3 variants, able to 
produce up to 13 different metabolites for ondansetron. Interestingly, the metabolite profile for 
amitriptyline, buspirone, ondansetron, propafenone, and repaglinide was different for the five variants 
studied, allowing the identification of key mutations changing the regio-specificity [‎51].  
4.2. Protein Engineering to Improve Catalytic Efficiency 
Although the protein engineering work of the last 7 years has been successful in producing several 
mutants of P450 BM3 able to turn over different drugs into different metabolites, much work is still 
needed to improve the catalytic performance of the potential biocatalysts. One of the most obvious 
tools will be to combine the different mutations now available and to introduce, where not present, the 
crucial changes in those positions known to improve the catalytic efficiency of the enzyme such as 
R47, Y51, F87 and A328V [‎93,‎94].  
Furthermore, different approaches of directed evolution such as DNA shuffling, already successful 
in the evolution of P450 enzyme (see for example [‎95–‎99]) could give rise to large libraries of mutants 
with an increased possibility to select the desired functions. Such approaches can include different 
bacterial homologous P450 fusion proteins such as CYP102A5 and A7 that have already been 
engineered to oxidise chlorzoxazone and diclofenac [‎100]. A chimeric library of synthetic P450s has 
already been created from the recombination of different homologous bacterial enzymes, CYP102A1, 
CYP102A2 and CYP102A3 [‎57,‎78,‎101]. The authors used a powerful structure-based algorithm called 
SCHEMA to identify fragments of proteins that can be recombined to minimize disruptive interactions 
that would prevent protein folding [‎101]. The heme domains generated by recombination were also 
fused with the three different reductase available. This approach has been used to generate a synthetic 
family of 16 P450 BM3 heme domain variants fused to three different reductases [‎57]. A cluster of 
chimeric enzymes showed high activity toward tolbutamide, propranolol and chlorzoxazone.  
Since the catalytic performance of P450 BM3 is also highly dependent on the electron transfer 
efficiency from NADPH to the substrate via the fused reductase containing the two flavin cofactors, 
new chimeric systems can be engineered by fusing at genetic level different domains, an approach 
known as “Molecular Lego” [‎102]. The so-called “optimized chimeragenesis” [‎103], a combination of 
synthetic P450s fused to different redox partner, can therefore offer a powerful tool to improve and 
optimize the biocatalytic properties for drug metabolite production. 
A very interesting observation was also made by the group of van Vugt-Lussenburg and  
co-workers [‎49]. They noticed that the metabolism of 3,4-methylenedioxymethylamphetamine and 
acetaminophen by P450 BM3 variants could be stimulated up to 70-fold by the addition of caffeine, a 
known activator of rat P450 3A2. They also observed homotropic cooperativity with testosterone and 
our group observed the same behaviour with the mutant A2 toward ibuprofen [‎66]. These data suggest 
that heterotropic and homotropic cooperativity, previously described for human P450 3A4 [‎104–110] 
can also take place in P450 BM3 [‎49]. One of the possible explanations for these observations is that 
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the mutants can accommodate more than one molecule in the active site and that the one molecule 
forces the other into a specific orientation, reduces substrate mobility and therefore triggers the reaction.  
The level of coupling for drug metabolite production by P450 BM3 variants has not been widely 
investigated until now, due to the fact that the attention has been focused to the introduction of new 
abilities in the bacterial enzyme. Nevertheless, very recently, the level of coupling for testosterone 
16β-hydroxylation has been reported to range from 13.5% to 83.5% in different mutants of P450  
BM3 [‎84]. Taking into account that the level of coupling for testosterone turnover by human P450 3A4 
has been reported to be 16% [‎111], the data mentioned above demonstrate that the bacterial enzyme 
can retain its coupling efficiency also when metabolizing human substrates. 
4.3. Substitution of the Costly NADPH Cofactor 
The need of the NADPH cofactor to drive electron transfer in the P450 catalysis significantly 
affects the cost of the scale-up of a biocatalytic process. For this reason, different solutions to this issue 
have been proposed. A simple and efficient solution uses hydrogen peroxide as oxidant in place of 
NADPH. In the presence of high peroxide concentrations the catalytic cycle of cytochromes P450 is 
forced to the peroxide shunt and the P450 works as a peroxide-dependent enzymes such as 
chloroperoxidase or P450BSb [‎112]. As early as in 1999 mutants of the bacterial P450cam from 
Pseudomonas putida able to hydroxylate naphthalene in the absence of cofactors through the 'peroxide 
shunt' pathway were created by directed evolution [‎113]. The mutants showed an activity improved by 
20-fold respect to the wild type enzyme [‎113]. Different studies on P450 BM3 have shown that the 
enzyme is able to use this pathway to hydroxylate different compounds [‎114,‎115]. Later, mutants of 
P450 BM3 were generated to metabolize propranolol into hydroxylated and N-despropylated forms 
using the peroxode shunt [‎78]. 
Another opportunity to reduce costs for a continuous use of NADPH is its regeneration by using 
dehydrogenases. The systems developed for P450 BM3 have been extensively reviewed by 
Whitehouse et al. [‎112]. The authors also reviewed the protein engineering work that has been done on 
P450 BM3 to accept the less expensive cofactor NADH. 
Biomimetic and less expensive cofactors, such as N-benzyl-1,4-dihydronicotinamide have also been 
shown to drive the catalysis of mutants of P450 BM3 [‎116]. 
An alternative to bypass the use of NADPH is the electrochemical reduction of the P450 enzyme. 
Despite the full bacterial enzyme or only the heme domain (BMP) have been immobilized on different 
electrode surfaces [‎117–119], only few reports have shown that the protein is able to turn over 
substrates by using the reducing equivalents donated by the electrode surface. Our group achieved 
catalysis on the substrate p-nitrophenol with the BMP immobilized on modified glassy carbon 
electrodes [‎120] and the chimeric protein BMP/Fld, where the redox protein flavodoxin from 
Desulfovibrio vulgaris was fused to BMP, resulted in a 6-fold increase of the amount of the reaction 
product p-nitrocatechol [‎120]. One key factor in electrochemically-driven P450 catalysis firstly 
reported by our group [‎121,‎122], is that strategies for immobilisation of electrode surfaces leading to 
high electron transfer values do not necessarily lead to catalytically active enzymes. Indeed slow 
heterogeneus electron transfer values allow for catalytic activity with the formation of product. This 
point has been reinforced by protein and electrode engineering that demonstrated the coupling 
Int. J. Mol. Sci. 2012, 13 15914 
 
efficiency can be modulated by controlling the electron transfer process from the electrode surface to 
the P450 enzyme [‎123]. These findings demonstrate how important is the control of the electron flow 
to the heme cofactor for the development of an efficient biocatalyst. Electrochemical catalysis was also 
achieved by the entrapment of P450 BM3 on polypyrrole on platinum and glassy carbon electrodes, 
reported to allow catalysis on the substrate p-nitrophenoxycarboxylic acid (pNCA) [‎124]. 
The need of NADPH was bypassed also by using a mediator such as cobalt(III)sepulchrate and zinc 
dust that serves as an electron source [‎125]. 
Other studies where NADPH was regenerated by non-enzymatic methods for monoxygenation 
reactions have been previously reviewed [‎126]. 
4.4. Immobilization and Scale-Up of the Bioprocess for Industrial Application 
The purified engineered P450 can be immobilized on a solid supports allowing the re-usage of the 
biocatalyst and most probably increasing the stability of the enzyme. In any case, a very stable enzyme 
is required, able to maintain its activity over time and in a wide range of temperature. For this reason, 
protein engineering has been aimed to create P450 BM3 variants with increased thermostability [‎127] 
also in combination with peroxygenase activity [‎128]. In this last case, 44 novel thermostable variants 
were generated showing half-lives of inactivation at 57 °C up to 108 times that of the most stable 
parent [‎128]. They were created by the recombination of stabilizing fragments and were demonstrated 
to metabolize also the drugs verapamil and astemizole [‎128]. Examples of immobilization of P450 
BM3 on different supports are present in the literature. 
Different matrices were used by Maurer and co-workers to immobilize the entire enzyme. The best 
method resulted encapsulation in a sol-gel matrix derived from tetraethoxy orthosilicate. The authors 
used also a cofactor recycling system based on formate dehydrogenase [‎129]. Sol-gel immobilisation of 
P450 BM-3 improved also enzymatic stability and activity toward b-ionone, octane and naphthalene [‎130]. 
The heme domain (BMP) of the mutant F87A was immobilized on two different mesoporous 
molecular sieves and showed activity using hydrogen peroxide as source of electrons and 12-pNCA 
and n-octane as substrate [‎130]. For this last substrate the activity of the immoblised protein was 2-fold 
higher compared to the free form. 
Recently, a mutant of P450 BM3, was immobilized on a DEAE-650S support and entrapped with  
k-carrageenan and a mediator, Zn/Co(III)sep, was used instead of NADPH. Zinc dust was used as 
electron source and catalase to remove hydrogen peroxide [‎131].  
In this work, a small-scale bioreactor was developed by immobilizing the mutant of P450 BM3 
named M9 carrying 8 point mutations. P450 BM3 M9 was used for the continuous conversion of  
3-phenoxytoluene in a plug flow reactor and the reactor was shown stable for 5 days with total 
turnover numbers over 2000 [‎131]. 
Attempts have been made to set up whole bacterial cells biotransformations based on P450 BM3. 
For example, a whole-cell biocatalyst based on cell-surface display of P450 BM3 has been developed. 
The method uses a fusion system consisting of P450 BM3 and an ice-nucleation protein (Inp) from 
Pseudomonas syringae to display the bacterial enzyme on the surface of Escherichia coli cells [‎132]. 
The surface-displayed P450 BM3 showed a kcat value lower than the purified enzyme (65%), but a 
similar Km value for the substrate 12-pNCA. 
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Escherichia coli BL21 were also use to co-express a quintuple mutant of P450 BM3 and a NADPH 
regenerating system consisting of a glucose facilitator from Zymomonas mobilis for uptake of 
unphosphorylated glucose and a NADP
+
-dependent glucose dehydrogenase from Bacillus megaterium. 
The biocatalyst was optimized and showed a 9-fold increased product formation rate toward the 
substrate alpha-pinene oxide [‎133]. 
The production of drug metabolites by cytochrome P450 BM3 has not yet reached the industrial 
scale since the limitations described above (cofactor requirement, low turnover rates) have not been 
totally overcome. Nevertheless, the introduction of the P450 BM3 variants in a host cell and the 
optimization of the fermentation conditions to obtain high levels of expression of the biocatalyst seems 
to be the most promising option [‎134,‎135]. Furthermore, biotransformations based on bacterial and 
yeast P450s have already reached the industrial scale [‎33] giving a reference point of yields of production 
required for a biological process to be exploited at industrial level. It can be noted that pravastatin is 
produced by hydroxylation of compactin catalysed by CYP105A3 from Streptomyces sp. [‎136]. The 
productivity reported is 15 mg L
−1
 h
−1
. 
5. Conclusions and Future Perspectives 
This review has shown that great progress has been made by protein engineering techniques in 
enabling the creation of a wide panel of P450 BM3 variants able to recognize and produce many drug 
metabolites generated by the major human liver P450 isoforms. Though more work is still currently 
being performed on this enzyme, also other bacterial homologues are becoming the center of studies 
aiming at increasing the variability of biocatalysts with the desired function. New experimental 
strategies based on computational methods are making possible the identification of the mutations 
required for the efficient production of the same metabolites generated by the human liver enzymes. 
Much work is still needed to increase the performance of these enzymes in terms of turnover and 
coupling efficiency. These hurdles not only can be overcome, but they also are less important when 
considering the huge advantages offered by the sustainable green approach offered by the use of 
engineered enzymes.  
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